Patents by Inventor Manfred Oberreither

Manfred Oberreither has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Vaccine formulations and uses thereof
    Patent number: 8795683
    Abstract: A liquid or liquid-frozen composition comprising: a modified vaccinia Ankara (MVA) virus or variant or derivative thereof and mannitol, wherein mannitol is the sole stabilization agent of the composition. The mannitol may provide a stabilizing effect at 0 to +10° C. or in a liquid-frozen composition, for example between ?10° C. and ?30° C. or between ?20° C. and ?23.5° C. The MVA may be used as a vaccine or for use in gene therapy, virotherapy, immunotherapy, or cancer therapy in a mammal, preferably a human.
    Type: Grant
    Filed: July 7, 2011
    Date of Patent: August 5, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Manfred Oberreither, Christa Tauer, Falko-Güenter Falkner
  • Vaccine Formulations and Uses Thereof
    Publication number: 20120201847
    Abstract: A liquid or liquid-frozen composition comprising: a modified vaccinia Ankara (MVA) virus or variant or derivative thereof and mannitol, wherein mannitol is the sole stabilization agent of the composition. The mannitol may provide a stabilizing effect at 0 to +10° C. or in a liquid-frozen composition, for example between ?10° C. and ?30° C. or between ?20° C. and ?23.5° C. The MVA may be used as a vaccine or for use in gene therapy, virotherapy, immunotherapy, or cancer therapy in a mammal, preferably a human.
    Type: Application
    Filed: July 7, 2011
    Publication date: August 9, 2012
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE
    Inventors: Manfred Oberreither, Christa Tauer, Falko-Guenter Falkner
  • Vaccine formulations and uses thereof
    Patent number: 7998488
    Abstract: A liquid or liquid-frozen composition comprising: a modified vaccinia Ankara (MVA) virus or variant or derivative thereof and mannitol, wherein mannitol is the sole stabilization agent of the composition. The mannitol may provide a stabilizing effect at 0 to +10° C. or in a liquid-frozen composition, for example between ?10° C. and ?30° C. or between ?20° C. and ?23.5° C. The MVA may be used as a vaccine or for use in gene therapy, virotherapy, immunotherapy, or cancer therapy in a mammal, preferably a human.
    Type: Grant
    Filed: November 14, 2008
    Date of Patent: August 16, 2011
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Manfred Oberreither, Christa Tauer, Falko-Guenter Falkner
  • VACCINE FORMULATIONS AND USES THEREOF
    Publication number: 20100124557
    Abstract: A liquid or liquid-frozen composition comprising: a modified vaccinia Ankara (MVA) virus or variant or derivative thereof and mannitol, wherein mannitol is the sole stabilization agent of the composition. The mannitol may provide a stabilizing effect at 0 to +10° C. or in a liquid-frozen composition, for example between ?10° C. and ?30° C. or between ?20° C. and ?23.5° C. The MVA may be used as a vaccine or for use in gene therapy, virotherapy, immunotherapy, or cancer therapy in a mammal, preferably a human.
    Type: Application
    Filed: November 14, 2008
    Publication date: May 20, 2010
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.
    Inventors: Manfred Oberreither, Christa Tauer, Falko-Guenter Falkner
  • Reagent used for determining factor VIII activity
    Patent number: 5506112
    Abstract: To determine the factor VIII activity of a sample, the latter is reacted with a reagent containing thrombin, factor IXa.beta., phospholipids and calcium ions so as to form a factor VIIIa-factor IXa-phospholipid-calicum ion-containing complex. This complex is reacted with factor X so as to obtain activated factor X. The obtained factor Xa is reacted with chromogenic substrate so as to form a substance to be determined spectrophotometrically. Complex formation and activation of factor X are effected in one stage: The sample is mixed with a mixture of human thrombin, phospholipids, calcium ions, human factor IXa.beta., human factor X and, if desired, human factor XIa and human factor XIIa, as a complex-forming reagent.
    Type: Grant
    Filed: January 10, 1992
    Date of Patent: April 9, 1996
    Assignee: Immuno Aktiengesellschaft
    Inventors: Hartmut Lang, Berta Moritz, Manfred Oberreither, Olga Lukas